Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Set 'Responsible' Price For Kymriah, Express Scripts Says

Executive Summary

Drug pricing critic Steve Miller, chief medical officer with Express Scripts, praises Novartis' gene therapy pricing and promotes benefits of amortized payments tied to outcomes.

You may also be interested in...



PBM Controls Coming To Medical Benefit Drugs? Express Scripts Acquisition Offers Platform

Express Scripts' plan to purchase medical benefits management company eviCore may give the PBM an opportunity to bring new pricing pressures to the medical benefit drug space.

Novartis Beats CAR-T Competitors To The Pricing Punch With Kymriah Approval

Novartis got a leg up on its competition Aug. 30 with an earlier-than-expected approval for Kymriah in pediatric ALL, ending the CAR-T pricing mystery with its $475,000 price tag, which the company is positioning as a relative bargain.

Novartis Begins CAR-T Payment Experiments With Outcomes-Based Contract With CMS

The Centers for Medicare and Medicaid Services will only pay for Kymriah if patients respond after one month. Novartis also pursuing similar contracts with private payers.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS121526

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel